Revitope

Revitope, an early stage biotechnology company, is focused on revolutionizing immunotherapy to effectively treat a wide range of cancers. The company's Programmable Antibody Circuits (PACs) aim to redirect T cells to the surface of cancer cells, activating a potent immune response while expanding antigenic targeting space. Founded in 2014 in the United States, Revitope secured an $8.50M Venture Round investment on 08 February 2016. The company's innovative approach to immune-based therapies in cancer treatment positions it as a promising player in the Biotechnology and Health Care industries. Revitope's groundbreaking work in precision immunotherapy has the potential to significantly impact the future of cancer treatment.